Viyash Scientific Limited · NSE:VIYASH
Viyash Scientific — SeQuent Scientific — Shareholder Meeting (September 2017)
19 slides from Viyash Scientific's shareholder meeting presentation, Sep 26, 2017
Slide 1: Warm Welcome to Shareholders - 32nd Annual General Meeting
WARM WELCOME TO SHAREHOLDERS 32nd Annual General Meeting 26th September 2017
Slide 2: Agenda
Agenda 1 2 3 4 Strategic Performance in Key Initiatives Agenda of Decision and FY17 for FY18 AGM Actions 2
Slide 3: Strategic Decision and Actions
Strategic Decision and Actions
Slide 4: FY17 - Building Capabilities for Sustainable Business
FY17 - Building Capabilities for Sustainable Business • No. 1 Animal health company in India • 9 World class manufacturing facilities • Vet API: Business scaled up, 23+ animal • Vizag (Alivira facility) received USFDA health APIs approval • Formulations: Strengthened footprints • Successful first ti
Slide 5: Creating India's largest Animal Health Company
Creating India’s largest Animal Health Company Revenue by Business Revenue by Geography Analytical services 1% Animal health API Human 17% health API Rest of Europe 30% World 38% 39% Animal health formulations Asia 52% 23% 5
Slide 6: Animal health API – Raising the benchmark in Quality
Animal health API – Raising the benchmark in Quality ▪ USFDA approval for Vizag facility – ‘First / Only dedicated USFDA approved Animal health facility in the World’ ▪ Consistent growth and diversifying product basket ▪ With over 23 commercial products across globe covering essential therapies ▪ 60
Slide 7: Animal Health Formulations – Establishing global leadership
Animal Health Formulations – Establishing global leadership ▪ Global presence with diversified portfolio ▪ Presence in 55+ countries with 4 manufacturing facilities ▪ 450+ products across 12 dosage forms ▪ Strong, growing foot-prints in key markets of India, South East Asia, MENA , Turkey, Europe an
Slide 8: Human API – Industry at an inflection point
Human API – Industry at an inflection point ▪ Differentiated strategy delivers ▪ Focus on Niche, small volume APIs with limited competition ▪ High Quality business with accelerating growth ▪ Well invested infrastructure with potential for future scalability ▪ Potential to scale capacities at all thr
Slide 9: Performance in FY17
Performance in FY17
Slide 10: Financial Indicators
Financial Indicators All values in Rs Mn Revenue from Operations EBITDA PAT 9151 11 881 6214 552 -180 4654 305 -500 FY14-15 FY15-16 FY16-17 FY14-15 FY15-16 FY16-17 FY14-15 FY15-16 FY16-17 10
Slide 11: Capital Employed
Capital Employed All values in Rs Mn Liabilities Assets Other Long- term liabilities, Working 819, 6% Capital, 1,881, 14% Net Debt, Fixed 3,042, 22% Assets, Investments, 6,033, 44% 3,644, 26% Shareholders fund, 9,940, 72% Goodwill, 2,242, 16% 11
Slide 12: Market Capitalization
Market Capitalization Stock Price Movement (Rs.) 146.4 128.9 102.3 38.0 26.0 31-Mar-13 31-Mar-14 31-Mar-15 31-Mar-16 31-Mar-17 Market Cap (Rs. Mn) 35,426.0 31,405.0 15,596.0 3,125.0 5,194.0 31-Mar-13 31-Mar-14 31-Mar-15 31-Mar-16 31-Mar-17 Historical market prices adjusted to reflect stock split 12
Slide 13: Key Initiatives for FY18
Soto Key Initiatives for FY18
Slide 14: Continuing to grow in FY18
Continuing to grow in FY18 All values in Rs Mn Sales Movement % Sales by segment 2,605 60% 68% Others Alivira 40% 32% Human API 1,687 Q1 FY17 Q1 FY18 API vs Formulation 38% 53% Others Forumations 62% 47% API Q1 FY17 Q1 FY18 Q1 FY17 Q1 FY18 14
Slide 15: Priorities FY18 – Progress Update
Priorities FY18 – Progress Update SAP GST Formulations R & D De-merger Successful go-live of Successful Completed Building one of India’s SAP on 3rd July for India implementation on 3rd development for 2 largest API Business operations July, along-with SAP go- products, 10+ in live progress 15
Slide 16: Building One of India's largest API Business
Building One of India’s largest API Business Solara Active Pharma Sciences- A standalone API Company Proposed transaction structure Transaction details Objective ▪ Setup critical size API business by De-merger of Human API business of SeQuent and the commodity API business of Strides Shasun into a n
Slide 17: Agenda for AGM
Agenda for AGM
Slide 18: Agenda for AGM
Agenda for AGM Item No Brief description of the Resolution Type of Resolution Adoption of Financial Statements (Standalone and Consolidated) for the 1 Ordinary year ended March 31, 2017 2 Reappointment of Dr. S Devendra, retiring Director Ordinary 3 Ratification of appointment of Statutory Auditors
Slide 19: Thank You
Thank You
SeQuent Scientific — Shareholder Meeting (September 2017) on 6ix